Mesoblast Limited (ASX:MSB) Enrolment Complete For 2nd Group Of Heart Failure Patients Treated With "Off-The-Shelf" Adult Stem Cells

Melbourne, Sep 22, 2009 AEST (ABN Newswire) - Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful completion of enrolment of the second group of 20 patients randomised to receive an increased dose of Revascor(TM), the proprietary allogeneic, or "off-the-shelf", universal adult stem cell product for congestive heart failure.

The placebo-controlled trial is being run by Mesoblast's United States-based associate company Angioblast Systems Inc. and will randomise up to 60 patients suffering from congestive heart failure to three groups receiving either a progressively increasing dose of the company's allogeneic adult stem cells or standard of care.

Treated patients in the second group received a dose of Revascor(TM) three times higher than in the first group. No cell or procedure-related adverse events have occurred in any of the 40 patients enrolled to date. Interim and final efficacy results will be reported when all patients meet the three and six-month endpoints.

Meeting clinical trial enrolment milestones on schedule continues to be an important objective of Mesoblast's equity-based investment in Angioblast. As a result of Angioblast's successful patient enrolment to date, in accordance with the terms of the Series B investment Mesoblast's equity holding in Angioblast has now converted into 38.4% common shares.

At Angioblast's next financing event, Mesoblast may seek to maintain or increase its shareholding.

Contact

Julie Meldrum Corporate Communications Director Mesoblast Limited Tel: +61-3-9639-6036 Mob: +61-419-228-128 Email: julie.meldrum@mesoblast.com www.mesoblast.com